CDT Settles $195K Manoira Evaluation Fee with 1.35M Shares; Issues 1.33M More for Services, Sarborg, and Severance
CDT is trading near its 52-week low of $0.066 (12% above the low) on elevated volume (41× avg).
Summary
CDT signed a $195,000 animal-health evaluation deal with Manoira, paying in 1,347,616 shares at $0.1447, and separately issued about 1.33 million more shares for consulting, Sarborg, and former CEO severance.
Key Events · M&A and Partnerships · CDT
-
Manoira Evaluation Agreement Signed
The six-month agreement calls for Manoira to test AZD1656 and AZD5904 in animal health alongside its cannabinoid products; a commercial license is optional and requires a separate signed agreement.
-
Fee Paid in Stock, Not Cash
To settle the $195,000 fee, CDT issued 1,347,616 shares at $0.1447 — roughly double today's $0.074 price, so the share count delivered is fixed but the value realized depends on the market.
-
Related-Party Counterparty
Dr. Andrew Regan, CDT's former CEO and a holder of more than 5% of common stock, is the sole director of Manoira; the filing states he receives no consideration from the transaction.
-
Additional Unregistered Issuances
The company issued 397,374 shares to a service provider, 437,779 Sarborg shares under the August 31, 2026 purchase agreement, and 499,616 severance shares to Dr. Regan in lieu of $65,000 — about 2.68 million shares total across the four issuances.
Analysis · CDT · Life Sciences
Why it matters: CDT is paying for an animal-health evaluation of its AZD1656 and AZD5904 compounds entirely in stock rather than cash, consistent with the $747K cash balance reported in the Q2 10-Q. The Manoira deal itself is small — a six-month, $195,000 evaluation with no obligation on either side to sign a commercial agreement, so the licensing upside is speculative. The bigger read-through is the share issuance: roughly 2.68 million new shares across four transactions, including 499,616 to former CEO Dr. Andrew Regan for severance and 1,347,616 to Manoira, whose sole director is Regan himself — a related-party payment to a former insider. Coming after the September 1-for-25 reverse split and the J.J. Astor convertible notes, the share count keeps climbing while cash stays thin.
How filings like this one have moved
In the 30 days to Oct 28, 2026, 30.7% of the 1698 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CDT was trading at $0.07 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $83.2K. The 52-week trading range was $0.07 to $20,123.75. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.